Alloy vs Refills
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Alloy
Best for women in menopause/perimenopause who want a Menopause Society-certified clinician AND the broadest brand+compounded GLP-1 formulary in our directoryStarting at $80/mo
Refills
Best for patients seeking a single account across multiple cash-pay telehealth categories (GLP-1 + ED + hair growth) and willing to verify state coverage + steady-state pricing during the intake before committingSide-by-Side Comparison
| Feature | Alloy | Refills |
|---|---|---|
| Overall Score | ✓7.4/10 | 6.9/10 |
| Starting Price | $80/mo | — |
| Editorial Rating | ✓3.7 ★ /5 | 3.5 ★ /5 |
| Features | ✓8 features | 7 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | — |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Alloy
Pros
- ✓Broadest GLP-1 formulary in our catalog: brand Wegovy + brand Zepbound + oral Wegovy + compounded semaglutide + compounded tirzepatide + compounded liraglutide
- ✓All consulting doctors are certified by The Menopause Society — only ~1,000 such certified practitioners exist among ~20,000 OB-GYNs in the US
- ✓Brand-name Wegovy starting at $199/mo and compounded liraglutide starting at $80/mo cover both ends of the price/access spectrum
- ✓STARTGLP1 promo code knocks $50 off the first month per the public site
Cons
- ✗Not available in Louisiana or Mississippi (verified) — readers in those two states should be routed elsewhere
- ✗Initial consultation is $49 and is separate from medication cost — readers should know there's a non-refundable upfront fee
- ✗Menopause-specialty framing — best fit for women in menopause/perimenopause, not the right product for men or younger women whose primary need is weight loss
Refills
Pros
- ✓LegitScript Certified seal verbatim ('LegitScript certified online pharmacy' alt text on the certification logo)
- ✓Provider claims operation across all 50 US states (with disclosed exclusions)
- ✓Multi-category telehealth platform (GLP-1 weight loss + ED + hair growth + daily wellness) — single-account convenience for patients seeking multiple modalities
- ✓Free shipping disclosed publicly
- ✓No insurance needed framing — cash-pay transparency
- ✓Webflow-hosted modern marketing site with structured Organization JSON-LD (signals operational maturity)
Cons
- ✗Steady-state monthly pricing for compounded semaglutide and tirzepatide NOT disclosed publicly — gated behind intake
- ✗Specific legal entity name + state of incorporation NOT publicly disclosed
- ✗Specific partner compounding pharmacy NOT named
- ✗Excluded state/region list (per the 'does not service the' caveat in their 50-state claim) NOT visible in marketing copy — patients should verify state coverage during intake
- ✗Brand-name GLP-1 lineup (Wegovy/Zepbound/Mounjaro/Ozempic/Foundayo) NOT addressed — compounded only
- ✗Lab work + ongoing-care touchpoints NOT clearly disclosed
- ✗Multi-category model (also operating in ED + hair) signals broad direct-to-consumer telehealth rather than a GLP-1-specialist platform
Our Verdict
Alloy edges out Refills with a higher overall score of 7.4/10 and is particularly strong for women in menopause/perimenopause who want a Menopause Society-certified clinician AND the broadest brand+compounded GLP-1 formulary in our directory. Refills remains a solid alternative, especially if you're looking for patients seeking a single account across multiple cash-pay telehealth categories (GLP-1 + ED + hair growth) and willing to verify state coverage + steady-state pricing during the intake before committing.
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.